ZimVie Inc (ZIMV) AI Stock Analysis

• Market Cap: $254.09M
• Dividend Yield: N/A
• Average Volume (3M): 151.52K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.35
• Revenue Growth: -32.70%
• EPS Growth: 94.89%
• Country: US
• Employees: 1,770
• Sector: Healthcare
• Sector Strength: 58
• Industry: Medical - Devices
• EPS (TTM): 0.27
• Shares Outstanding: 27,921,549
• 10 Day Avg. Volume: 104,043
• 30 Day Avg. Volume: 151,520
• PEG Ratio: 0.12
• Price to Book (P/B): 0.32
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -127.02
• Enterprise Value/Market Cap: 2.83
• Enterprise Value/Revenue: 0.38
• Enterprise Value/Gross Profit: 2.50
• Enterprise Value/Ebitda: 4.45
• 1Y Price Target: $11.67
• Price Target Upside: 28.24% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 4

• Rating: 51 Neutral
• Price Target: $9.00 ▼(-1.10%Downside)

The overall score reflects the financial challenges ZimVie Inc. faces, with declining revenues and negative margins posing significant risks. However, improvements in profitability and cost management, as highlighted in the earnings call, provide some optimism. Technical indicators suggest caution, and the valuation metrics indicate high risk. Investors should weigh the potential for strategic growth against ongoing financial difficulties.

Positive Factors

Acquisition

In early April, ZIMV acquired a distributor in Costa Rica for $3.3M which should be accretive to revenue and margins.

Market Stability

The overall health of the dental market was discussed, indicating stability and potential growth opportunities for Zimvie Inc.

Profitability

Profitability was strong and ZIMV is able to absorb a modest impact from tariffs.

Negative Factors

Product Weakness

Implants and scanners were the two weakest product groups in the quarter.

Revenue Performance

ZIMV missed consensus revenue while adjusted EBITDA beat expectations in 1Q25.

ZimVie Inc Business Overview & Revenue Model

Company Description

ZimVie Inc (ZIMV) is a medical technology company that operates in the healthcare sector, focusing on the development, manufacturing, and marketing of a broad range of products and solutions for the dental and spine markets. The company is dedicated to enhancing patient outcomes and improving the quality of life through its innovative and comprehensive offerings. ZimVie's portfolio includes dental implants, biomaterials, digital dentistry solutions, and spinal fusion and fixation products, serving healthcare professionals and patients worldwide.

How the Company Makes Money

ZimVie Inc makes money by selling its medical technology products and solutions primarily in the dental and spine markets. The company's revenue model is based on direct sales to healthcare providers, hospitals, and clinics, where it offers a range of products such as dental implants, biomaterials, and digital dentistry solutions. Additionally, ZimVie generates income through the sale of spinal fusion and fixation devices, which are used by surgeons and healthcare facilities in various spinal surgeries. The company may also benefit from strategic partnerships and collaborations that expand its market reach and product offerings, contributing to its overall earnings.

ZimVie Inc Financial Statement Overview

Summary

ZimVie Inc. is facing challenges with declining revenues and negative net profit margins, despite some improvements in EBITDA margin and equity ratios. The high leverage and negative ROE highlight financial risks.

Income Statement

ZimVie Inc. has struggled with declining revenues, from $1,014.6 million in 2021 to $443.6 million in TTM. The net profit margin is negative, indicating ongoing losses, though there is a slight improvement in EBITDA margin in TTM. This reflects challenges in maintaining both revenue levels and profitability.

Balance Sheet

The debt-to-equity ratio is relatively high at approximately 0.59 in TTM, indicating significant leverage. However, the equity ratio has improved to 52.97%, showing moderate financial stability. The company’s ROE remains negative, suggesting inefficiencies in generating returns on equity.

Cash Flow

The company has managed a positive free cash flow in TTM, although it has decreased from previous periods. Operating cash flow to net income ratio is not favorable due to negative net income, but cash flow management shows some resilience.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
443.55M	449.75M	457.43M	913.86M	1.01B	912.40M
	Gross Profit
287.56M	287.45M	290.38M	613.08M	628.80M	599.50M
	EBIT
-17.07M	-20.66M	-30.94M	-50.85M	-73.60M	-67.10M
	EBITDA
36.95M	29.61M	91.07M	79.16M	28.70M	-86.70M
	Net Income Common Stockholders
-19.54M	-25.82M	-393.28M	-63.88M	-95.30M	-179.00M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
66.75M	74.97M	71.51M	89.60M	100.40M	27.40M
	Total Assets
745.78M	753.67M	1.21B	1.64B	1.83B	1.95B
	Total Debt
232.71M	232.57M	521.93M	564.14M	57.90M	89.20M
	Net Debt
165.96M	157.60M	450.42M	474.54M	-42.50M	61.80M
	Total Liabilities
350.66M	371.97M	795.85M	883.45M	375.30M	458.70M
	Stockholders Equity
395.12M	381.71M	409.49M	758.60M	1.45B	1.49B
Cash Flow		Free Cash Flow
5.74M	7.49M	24.66M	-1.92M	7.70M	47.70M
	Operating Cash Flow
11.77M	14.17M	37.15M	24.63M	64.30M	86.00M
	Investing Cash Flow
284.49M	282.30M	-15.17M	-28.66M	-60.30M	-49.50M
	Financing Cash Flow
-294.36M	-294.67M	-25.67M	-1.31M	72.30M	-46.50M

ZimVie Inc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 9.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ZIMV, the sentiment is Negative. The current price of 9.1 is above the 20-day moving average (MA) of 9.01, below the 50-day MA of 9.11, and below the 200-day MA of 12.90, indicating a neutral trend. The MACD of 0.04 indicates Negative momentum. The RSI at 48.31 is Neutral, neither overbought nor oversold. The STOCH value of 56.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ZIMV.

ZimVie Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
STE	80 Outperform	$23.74B	38.03	9.46%	0.94%	0.32%	64.36%
PODD	76 Outperform	$21.44B	54.82	37.92%	―	23.49%	71.25%
ZBH	70 Outperform	$18.06B	20.23	7.31%	1.05%	3.30%	-2.39%
LIVN	66 Neutral	$2.50B	30.62	-19.69%	―	7.97%	-592.40%
Sector *	54 Neutral	$5.37B	3.26	-45.10%	3.30%	16.81%	0.02%
ZIMV	51 Neutral	$254.09M	―	-6.35%	―	-32.70%	94.89%
OFIX	49 Neutral	$430.99M	―	-27.82%	―	5.85%	-8.92%

ZimVie Inc Corporate Events

ZimVie Inc Holds Annual Shareholders Meeting

ZimVie Inc. held its annual shareholders meeting on May 7, 2025, where key decisions were made regarding company governance and executive compensation. Shareholders elected a Class III director, ratified PricewaterhouseCoopers LLP as the independent auditor for 2025, and approved the executive compensation plan on a non-binding advisory basis.

The most recent analyst rating on (ZIMV) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on ZimVie Inc stock, see the ZIMV Stock Forecast page.

ZimVie Inc Reports Q1 2025 Financial Results

On May 8, 2025, ZimVie Inc. reported its financial results for the first quarter of 2025, showing net sales of $112.0 million, which marked a 5.2% decrease compared to the same period in 2024. Despite a net loss of $2.6 million, the company improved its net loss margin significantly from the previous year. Adjusted EBITDA increased to $17.6 million, reflecting a 15.7% margin. The company remains focused on operational efficiency and profitability improvements, aiming for a return to top-line growth.